Sonata Shows Advantage In Sleep Induction Over Comparable Drugs - EPAR
Executive Summary
Wyeth-Ayerst's hypnotic agent Sonata (zaleplon) showed an advantage over comparable insomnia agents in the induction of sleep, the Committee for Proprietary Medicinal Products stated in its European Public Assessment Report for the product, released May 5.
You may also be interested in...
Wyeth Sonata Short-Term Psychomotor Symptoms Allows Mid-Night Dosing
The short-term psychomotor effects of Wyeth-Ayerst's insomnia drug Sonata (zaleplon) allow late night dosing without significant lingering effects the following day.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011